share_log

Akili Analyst Ratings

Benzinga ·  Aug 11, 2023 09:06
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/11/2023 260.36% Credit Suisse → $4 Reiterates Outperform → Outperform
01/25/2023 170.27% Morgan Stanley $2 → $3 Maintains Equal-Weight
12/28/2022 80.18% Morgan Stanley → $2 Initiates Coverage On → Equal-Weight
11/18/2022 80.18% B of A Securities → $2 Initiates Coverage On → Neutral
11/15/2022 305.41% Credit Suisse $4 → $4.5 Maintains Outperform
10/25/2022 350.45% Credit Suisse → $5 Initiates Coverage On → Outperform
09/06/2022 Cowen & Co. Initiates Coverage On → Outperform

What is the target price for Akili (AKLI)?

The latest price target for Akili (NASDAQ: AKLI) was reported by Credit Suisse on August 11, 2023. The analyst firm set a price target for $4.00 expecting AKLI to rise to within 12 months (a possible 260.36% upside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Akili (AKLI)?

The latest analyst rating for Akili (NASDAQ: AKLI) was provided by Credit Suisse, and Akili reiterated their outperform rating.

When is the next analyst rating going to be posted or updated for Akili (AKLI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akili, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akili was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.

Is the Analyst Rating Akili (AKLI) correct?

While ratings are subjective and will change, the latest Akili (AKLI) rating was a reiterated with a price target of $0.00 to $4.00. The current price Akili (AKLI) is trading at is $1.11, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment